Evaluation of the effects of anti-pruritic drugs on scratch responses using histamine H1 receptor-deficient mice

An electrophysiological method for evaluation of topical antipruritic drugs on itch-related neuronal activities in the spinal cord in hairless mice

To evaluate the effects of antipruritic drugs, it is important to determine whether the neural responses induced by physiological itch stimuli are suppressed. Although there are several behavioral assessments for topical antipruritic drugs applied to the skin, there are few established methods at neuronal levels using in vivo electrophysiological recordings for predicting local efficacy of antipruritic drugs for cutaneous application. To establish an assessment of topical antipruritic drugs applied to skin using in vivo extracellular recording from neurons in the superficial dorsal horn, we examined the relationships between itch-related biting behavior and spinal neuronal responses elicited by intradermal injection of pruritogen serotonin (5-HT) in hairless mice. The efficacy of topical occlusive application of local anesthetics was also evaluated by an in vivo electrophysiological method. 5-HT significantly increased the firing frequency in spinal neurons. The spinal firing frequency time course was similar to that of the biting behavior after the 5-HT injections. The 5-HT-induced spinal responses were significantly decreased by topical occlusive application of lidocaine or a Nav 1.7 channel blocker to the calf. The intradermal 5-HT injection-induced spinal neuronal responses appeared to be suppressed by topical occlusive application of lidocaine or a Nav1.7 channel blocker. The electrophysiological method for evaluating topical antipruritic drugs may be beneficial in assessing local effects on the skin.

Peripheral and Central Mechanisms of Itch

Itch is a unique sensory experience that is encoded by genetically distinguishable neurons both in the peripheral nervous system (PNS) and central nervous system (CNS) to elicit a characteristic behavioral response (scratching). Itch interacts with the other sensory modalities at multiple locations, from its initiation in a particular dermatome to its transmission to the brain where it is finally perceived. In this review, we summarize the current understanding of the molecular and neural mechanisms of itch by starting in the periphery, where itch is initiated, and discussing the circuits involved in itch processing in the CNS.

Co-amorphous Formation Induced by Combination of Tranilast and Diphenhydramine Hydrochloride

In this study, we investigated the formation of a co-amorphous system of tranilast (TRL) and diphenhydramine hydrochloride (DPH), which are drugs used for treating allergies and inflammation. The crystallization from undercooled melts of the drugs and drug mixtures was evaluated by thermal analysis. Both drugs in the amorphous state underwent crystallization on heating, although the mixture remained in the amorphous state, indicating the formation of a co-amorphous system. The physicochemical properties of co-amorphous TRL-DPH prepared by the melting-cooling process were studied. The glass transition temperature of co-amorphous TRL-DPH deviated from the theoretical value. The enthalpy relaxation rate of the amorphous drugs, which reflected the molecular mobility, was reduced by the formation of a co-amorphous system. The intermolecular interactions between TRL and DPH in the co-amorphous system were measured by the change in the IR spectra. These results were consistent with the high physical stability. The co-amorphous sample remained in the amorphous state for over 30 days at 40°C, whereas the amorphous drugs showed rapid crystallization. Our findings demonstrate that TRL and DPH form a co-amorphous system, which dramatically decreases their crystallization without an excipient.

The role of the Mrgpr receptor family in itch

Itch is a complex sensory modality that can be evoked by an extremely diverse set of stimuli and has multiple components of disease etiology. Thus, determining the basic molecular and cellular players is essential before we can tackle the more complex aspects of itch. The identification of novel itch receptors has been extremely fruitful and has uncovered novel signaling pathways and pruritogens. Mrgprs encode a family of G protein-coupled receptors, many of which are expressed specifically in sensory nerves and function as itch receptors in mediating histamine-independent itch. In this chapter, we will review the discovery of the receptor family, their specific expression, their roles as itch receptors, and the itch-inducing agonists. Furthermore, we will summarize the results indicating that Mrgpr-expressing sensory neurons are itch-sensing neurons. In the end we will discuss the role of Mrgprs and Mrgpr-positive neurons in chronic itch.

Participation of proteinase-activated receptor-2 in passive cutaneous anaphylaxis-induced scratching behavior and the inhibitory effect of tacrolimus

Proteinase-activated receptor-2 (PAR2) may be an important regulator of skin mast cell function during cutaneous inflammation and hypersensitivity. However, little is known of the role of PAR2 in allergic pruritus, because mast cells, which are thought to be responsible for this symptom, can release a number of different pruritogens. In the present study, we investigated the effects of several agents on passive cutaneous anaphylaxis-induced scratching behavior in ICR mice. As a result, cetirizine and ketanserin produced dose-dependent inhibition of scratching behavior induced by passive cutaneous anaphylaxis. Combined cetirizine with ketanserin exhibited significant inhibitory effects for the number of passive cutaneous anaphylaxis-induced scratching behavior. Pretreatment of the experimental animals with PAR2-neutralizing antibody and protease inhibitor leupeptin significantly inhibited passive cutaneous anaphylaxis-induced scratching behavior. Furthermore, we found that topical application of tacrolimus significantly reduced the number of scratching behavior induced by passive cutaneous anaphylaxis in a dose-dependent manner. Combined cetirizine with tacrolimus also exhibited significant inhibitory effects for the number of passive cutaneous anaphylaxis-induced scratching behavior. Tacrolimus in doses of 3% and 10% significantly inhibited tryptase-induced scratching behavior. These results suggest that PAR2 may be involved in passive cutaneous anaphylaxis-induced scratching behavior and tacrolimus produces an anti-allergic pruritus effect in ICR mice.

Role of histamine H(4) receptor in allergic conjunctivitis in mice

We investigated the character of histamine H(1) receptor and H(4) receptor in allergic conjunctivitis. Histamine is the most important mediator in allergic conjunctivitis. We measured eye scratching behavior and allergic-like symptoms score, that is, hyperemia and edema in ICR mice, and examined which receptors intimately involved in allergic conjunctivitis. Histamine caused a dose-dependent eye scratching behavior and allergic-like symptoms. Histamine H(1) receptor antagonist (levocabastine) and H(4) receptor antagonist (JNJ7777120) inhibited eye scratching behavior and histamine H(1) receptor antagonist inhibited allergic-like symptoms induced by histamine. Additionally, combination of levocabastine and JNJ7777120 caused more potent inhibition in allergic conjunctivitis. On the other hand, both selective histamine H(1) receptor agonist (HTMT) and selective H(4) receptor agonist (4-methylhistamine) induced a dose-dependent eye scratching behavior and allergic-like symptoms. JNJ7777120 inhibited the effect of HTMT. However, levocabastine caused no inhibition on the response of 4-methylhistamine. H(4) receptor was closely related with allergic conjunctivitis. H(4) receptor antagonists may be effective in allergic conjunctivitis which showed no inhibition by histamine H(1) receptor antagonists.

The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines

Histamine has a key role in allergic inflammatory conditions. The inflammatory responses resulting from the liberation of histamine have long been thought to be mediated by the histamine H1 receptor, and H1-receptor antagonists--commonly known as antihistamines--have been used to treat allergies for many years. However, the importance of histamine in the pathology of conditions such as asthma and chronic pruritus may have been underestimated. Here, we review accumulating evidence suggesting that histamine indeed has roles in inflammation and immune function modulation in such diseases. In particular, the discovery of a fourth histamine receptor (H4) and its expression on numerous immune and inflammatory cells has prompted a re-evaluation of the actions of histamine, suggesting a new potential for H4-receptor antagonists and a possible synergy between H1 and H4-receptor antagonists in targeting various inflammatory conditions.

Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus

BACKGROUND

Histamine is a potent mediator of itch in humans, yet histamine H(1) receptor antagonists have been shown to be of limited use in the treatment of certain chronic pruritic diseases. The histamine H(4) receptor is a recently described histamine receptor, expressed on hematopoietic cells, linked to the pathology of allergy and asthma.

OBJECTIVE

The contribution of the novel histamine H(4) receptor to histaminergic and allergic pruritus was investigated.

RESULTS

Histamine and a selective histamine H(4) receptor agonist caused scratching responses in mice, which were almost completely attenuated in histamine H(4) receptor knockout mice or by pretreatment with the selective histamine H(4) receptor antagonist, JNJ 7777120. Pruritus induced by allergic mechanisms was also potently inhibited with histamine H(4) receptor antagonist treatment or in histamine H(4) receptor knockout mice. In all cases, the inhibitory effect of histamine H(4) receptor antagonist was greater than those observed with histamine H(1) receptor antagonists. The histamine H(4) receptor-mediated pruritus was shown to be independent of mast cells or other hematopoietic cells and may result from actions on peripheral neurons.

CONCLUSION

These results demonstrate that the histamine H(4) receptor is involved in pruritic responses in mice to a greater extent than the histamine H(1) receptor.

CLINICAL IMPLICATIONS

Histamine H(4) receptor antagonists may have therapeutic utility for treating chronic pruritic diseases in humans where histamine H(1) receptor antagonists are not effective.

A new chronic itch model accompanied by skin lesions in hairless mice

The present study was performed to develop a new chronic itch model accompanied by skin lesions using hairless mice. The effects of some drugs on the itch response in this model were also studied. 2,4,6-Trinitrochlorobenzene (TNCB) was applied repeatedly on the rostral back of sensitized hairless mice every 2 days for 54 days, and the scratching behavior was observed on day 0, 18, 36 and 54. The skin symptoms and total IgE level were also observed. The number of scratches observed at 24 and 48 h after TNCB challenge was increased gradually from day 18 to day 54. An intimate relationship was observed between the number of scratches and the skin score at 48 h after TNCB on day 54. The skin symptoms and total IgE levels were also elevated gradually from day 18 to day 54. Chlorpheniramine, cyproheptadine and methysergide caused no effect on the scratching behavior accompanied by skin lesions at 48 h after TNCB challenge, even at a high dose. On the other hand, L-733,060, naloxone, naltrexone, prednisolone and dexamethasone caused a significant inhibition of the scratching behavior induced by TNCB. Therefore, this model may be useful to evaluate the effects of drugs on the itch response accompanied by skin lesions, such as atopic dermatitis.

Characteristics of scratching behavior induced by some chemical mediators in hairless mice

To find the characteristics of scratching behavior in hairless mice (HR-1), compound 48/80 and some putative chemical mediators of allergic reaction were injected intradermally into the backs of mice, and the number of scratching behaviors was measured. As reference mice, NC/Nga, ICR, and ddY mice were used. Scratching behavior in HR-1 and ICR mice was increased dose-dependently by compound 48/80. The same result was also observed with NC/Nga and ddY mice. However, the response in NC/Nga and ddY mice was far less than those of HR-1 and ICR mice. Similar to NC/Nga and ddY mice, HR-1 mice showed less sensitivity to histamine than ICR mice. On the other hand, the HR-1 mice showed a high response to serotonin compared with those of the NC/Nga and ddY mice. The scratching behavior in HR-1 mice induced by substance P was increased, but the effect was less potent than those in NC/Nga, ICR, and ddY mice. These results suggest that the scratching behavior induced by compound 48/80 in HR-1 mice is mainly attributable to serotonin.

Effect of loratadine on mouse models of atopic dermatitis associated pruritus

To confirm the effectiveness of loratadine for relieving pruritus in atopic dermatitis, we examined the effect of this drug using animal models of atopic dermatitis associated pruritus in ICR and hairless mice. As for the results, in ICR mice, single oral administration of loratadine at a dose of 5 or 10 mg/kg significantly inhibited the dorsal scratching behavior induced by histamine or an antigen, and the effect of loratadine was more potent than that of fexofenadine and chlorpheniramine. In hairless mice, oral administration of loratadine at a dose of 10 mg/kg for 6 days significantly inhibited the facial scratching behavior induced by the feeding of a low magnesium diet. Furthermore, oral administration of loratadine at a dose of 10 mg/kg for 7 days also significantly inhibited the histamine-induced scratching behavior in the same animals. These results indicate that loratadine may be effective in preventing pruritus associated with atopic dermatitis.